SEC Form 4 · accession 0000899243-18-001390

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jung Choi

Officer — See Remarks

Period of report

Jan 16, 2018

Accepted (ET)

Jan 18, 2018 · 7:59 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001629137

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 16, 2018	M	2,000	—	A	137,255	D
Common Stock^F2	Jan 16, 2018	F	877	$52.10	D	136,378	D
Common Stock	Jan 17, 2018	M	198	$3.40	A	136,576	D
Common Stock	Jan 17, 2018	M	601	$3.40	A	137,177	D
Common Stock	Jan 17, 2018	M	601	$3.40	A	137,778	D
Common Stock	Jan 17, 2018	S	1,400	$52.85	D	136,378	D
Common Stock^F4	Jan 17, 2018	S	1,600	$52.85	D	134,778	D
Common Stock	holding	—	—		—	25,000	I	By Trust

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F5	—	Jan 16, 2018	M	2,000	D	—	—	Common Stock	2,000	13,000	D
Employee Stock Option (Right to Buy)^F6	$3.40	Jan 17, 2018	M	198	D	—	Apr 8, 2025	Common Stock	198	75,756	D
Employee Stock Option (Right to Buy)^F7	$3.40	Jan 17, 2018	M	601	D	—	Apr 8, 2025	Common Stock	601	5,079	D
Employee Stock Option (Right to Buy)^F8	$3.40	Jan 17, 2018	M	601	D	—	Apr 8, 2025	Common Stock	601	5,079	D

Explanation of responses

F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs.
F3This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F4These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter.
F5On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F625% of the shares subject to this option vested and became exercisable on April 6, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
F7On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
F8On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.

Remarks

Chief Business and Strategy Officer